Clinical trial
Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00267553 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Lead sponsor
- Intarcia Therapeutics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 30, 2005
- Completion date
- June 30, 2006
- Enrollment
- 200
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.